N/A
N=214
Vision Performance Evaluation of TECNIS EYHANCE™ With TECNIS SIMPLICITY™ Compared to TECNIS® 1-piece Intraocular Lenses
Cataract
Bottom Line
View on ClinicalTrials.gov: NCT05025345 ↗Enrolled (actual)
214
Serious AEs
4.2%
Results posted
Aug 2023
Primary outcome: Primary: MONOCULAR BEST-CORRECTED DISTANCE VISUAL ACUITY (BCDVA) — -0.017; -0.029 LogMAR
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Tecnis Eyhance (Device); Tecnis 1 piece IOL (Device)
- Age
- Adult, Older Adult · 22+ yrs
- Sex
- All
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
- Primary completion
- Jun 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY MONOCULAR BEST-CORRECTED DISTANCE VISUAL ACUITY (BCDVA) |
-0.017; -0.029 | — |
| SECONDARY MONOCULAR DISTANCE-CORRECTED INTERMEDIATE VISUAL ACUITY AT 66 CM (DCVA66) |
0.235; 0.348 | <0.0001 sig |
Summary
This study is a 6-month, prospective, multicenter, bilateral, randomized subject- and evaluator-masked, clinical investigation of the TECNIS Eyhance IOL versus the TECNIS 1-piece IOL.
The study will be conducted at up to 15 sites in the U.S.A and will enroll approximately 220 subjects to achieve approximately 200 randomized and bilaterally implanted subjects, resulting in approximately 100 evaluable subjects in each lens group at 6 months. Subjects are to be implanted with the same IOL in both eyes: TECNIS Eyhance IOL or the TECNIS 1-Piece IOL. The eye implanted first will be considered the primary study eye.
Eligibility Criteria
Inclusion Criteria
- Minimum 22 years of age
- Bilateral cataracts for which posterior chamber IOL implantation has been planned
- Preoperative best corrected distance visual acuity (BCDVA) of 20/40 Snellen or worse with or without a glare source
- Potential for postoperative best corrected visual acuity of 20/30 Snellen or better
- Corneal astigmatism parameters:
- Normal corneal topography and no irregular corneal astigmatism
- Postoperative astigmatism can be surgically managed to be less than 1 D in each eye
- Clear intraocular media other than cataract in each eye
- Availability, willingness, ability, and sufficient cognitive awareness to comply with examination procedures and study visits
- Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries
- Ability to understand and respond to a questionnaire in English
Exclusion Criteria
- Any conditions or circumstances, including those specified in the TECNIS Eyhance™ IOL Directions for Use, that, in the opinion of the investigator, may increase risk over benefit or result in an adverse event during the study.
- Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.)
- Concurrent participation or participation within 60 days prior to preoperative visit in any other clinical trial
- Desire for monovision correction
Data sourced from ClinicalTrials.gov (NCT05025345). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.